Non-amnestic Alzheimer disease

Overview

Diagnosis

Management

Special Populations

Key Recommendations

References

Showing 100 most recent of 282 indexed papers.

1 Jung YH, Cho J, Lee SY, Seo HE, Tak K, Kim WR et al.. Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline. Neurology 2026. link 2 Bamberger TC, Diedrich JK, Jung T, Lane JB, Schaefer JH, Lander GC et al.. A Covalent Protein Painting Assay Differentiates Amyloid-β Polymorphs in Alzheimer Disease. Journal of proteome research 2026. link 3 Bhuiya J, Shibly AZ, Sheikh AM, Tabassum S, Abdullah FB, Fahmida J et al.. Deposition of aggregated cystatin C-amyloid-β complexes and reduced cathepsin B activity modulate cerebral amyloid angiopathy pathogenesis. Journal of neuropathology and experimental neurology 2026. link 4 Isotalo HK, Lehtovaara JK, Ekblad LL, Nuotio MS, Langén VLJ. Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients. The Annals of pharmacotherapy 2026. link 5 Kancheva AK, Lyall DM, Tsvetanov KA, Kancheva IK, Mavromati K, Koychev I et al.. Cardiovascular Risk as a Moderator of the Relationship Between Plasma Alzheimer Disease Biomarkers and Cognitive Status. Journal of the American Heart Association 2026. link 6 Vejdani-Jahromi M, Calle E, Ganem O, Rohatgi S, Farzaneh H, Griffin H et al.. Relationship between . AJNR. American journal of neuroradiology 2026. link 7 Seixas-Lima B, Binns M, Black SE, Freedman M, Kumar S, Lahiri D et al.. The Relationship between Age and Cognitive Subtypes of Alzheimer Syndrome and Related Dementias. Dementia and geriatric cognitive disorders 2026. link 8 Gerlach LB, Zhang L, Kim HM, Teno J, Maust DT. Benzodiazepine or Antipsychotic Use and Mortality Risk Among Patients With Dementia in Hospice Care. JAMA network open 2025. link 9 Xing X, Wang K, Dong X. Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system]. Alzheimer's research & therapy 2025. link 10 Irizarry M, Surick I, Michael A, D Kramer L. Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. Alzheimer's research & therapy 2025. link 11 Donati M, Boccia A, De Ponti F, Poluzzi E, Raschi E. Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. Alzheimer's research & therapy 2025. link 12 Li Z, Gu J, Du Z, Lu R, Jiang Y, Zhu H. Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data. Journal of affective disorders 2025. link 13 Morotti A, Pilotto A, Zanola D, Galli A, Caratozzolo S, Gasparotti R et al.. Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria. Neurology 2025. link 14 Broughton P, Niles A, Imeh-Nathaniel A, Imeh-Nathaniel S, Goodwin RL, Roley LT et al.. Risk factors of male and female Alzheimer's disease patients with neuropsychiatric symptoms. Geriatric nursing (New York, N.Y.) 2025. link 15 Bermudez C, Lesnick TG, More SS, Ramanan VK, Knopman DS, Rabinstein AA et al.. Optical Coherence Tomography Angiography Retinal Imaging Associations With Burden of Small Vessel Disease and Amyloid Positivity in the Brain. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2025. link 16 Greenberg SM, Aparicio HJ, Furie KL, Goyal MS, Hinman JD, Kozberg M et al.. Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association. Stroke 2025. link 17 Kwak IY, Kim KS, Min HJ. Association of gustatory dysfunction and Alzheimer. Rhinology 2024. link 18 Ferrarelli LK. Biasing microglia to help, not hurt. Science signaling 2024. link 19 Desai BT. Alzheimer Disease research and Aβ56: The star that never was. Indian journal of medical ethics* 2024. link 20 Piller C. 'Damning' FDA inspection report undermines Alzheimer's drug. Science (New York, N.Y.) 2024. link 21 Piller C. Firm misled investors on Alzheimer's drug, SEC charges. Science (New York, N.Y.) 2024. link 22 Aksoyalp ZŞ, Nemutlu-Samur D. Comparative Post-Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database. International journal of geriatric psychiatry 2024. link 23 Ferrarelli LK. Get moving to clear β-amyloid. Science signaling 2023. link 24 Couzin-Frankel J. Alzheimer's drug approval gets a mixed reception. Science (New York, N.Y.) 2023. link 25 Stolz R, Krause O, Junius-Walker U, Thürmann P, Fuchs A, Wilm S et al.. The role of qualification and quality management in the prescription of antipsychotics and potentially inappropriate medication (PIM) in nursing home residents in Germany: results of the HIOPP-3-iTBX study. Aging clinical and experimental research 2023. link 26 Prosser L, Macdougall A, Sudre CH, Manning EN, Malone IB, Walsh P et al.. Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration. Neurology 2023. link 27 Collins AM. Shining a Light on Alzheimer Disease and Other Dementias. The American journal of nursing 2022. link 28 Lu WH, Giudici KV, Morley JE, Guyonnet S, Parini A, Aggarwal G et al.. Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. GeroScience 2022. link 29 Davis MA, Chang CH, Simonton S, Bynum JPW. Trends in US Medicare Decedents' Diagnosis of Dementia From 2004 to 2017. JAMA health forum 2022. link 30 Gianattasio KZ, Moghtaderi A, Lupu D, Prather C, Power MC. Evaluation of Federal Policy Changes to the Hospice Benefit and Use of Hospice for Persons With ADRD. JAMA health forum 2022. link 31 Ferreira TR, Lopes LC, Motter FR, de Cássia Bergamaschi C. Potentially inappropriate prescriptions to Brazilian older people with Alzheimer disease: A cross-sectional study. Medicine 2021. link 32 Efjestad AS, Ihle-Hansen H, Hjellvik V, Engedal K, Salvesen Blix H. Sex differences in psychotropic and analgesic drug use before and after initiating treatment with acetylcholinesterase inhibitors. PloS one 2021. link 33 Wei YJ, Schmidt S, Chen C, Fillingim RB, Reid MC, DeKosky S et al.. Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia. Alzheimer's research & therapy 2021. link 34 Kho J, Ioannou A, Mandal AKJ, Cox A, Nasim A, Metaxa S et al.. Long term use of donepezil and QTc prolongation. Clinical toxicology (Philadelphia, Pa.) 2021. link 35 Hansen RJ, Talmage CA, Thaxton SP, Knopf RC. Enhancing older adult access to lifelong learning institutes through technology-based instruction: A brief report. Gerontology & geriatrics education 2020. link 36 Joung KI, Shin JY, Kim S, Cho SI. Anticholinergic Use Among the Elderly With Alzheimer Disease in South Korea: A Population-based Study. Alzheimer disease and associated disorders 2020. link 37 Graff-Radford J, Lesnick T, Rabinstein AA, Gunter J, Aakre J, Przybelski SA et al.. Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging. Neurology 2020. link 38 Tanaka T, Stephenson MC, Nai YH, Khor D, Saridin FN, Hilal S et al.. Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease. European journal of nuclear medicine and molecular imaging 2020. link 39 Lu X, Moeini M, Li B, Thorin É, Lesage F. Hypertension accelerates cerebral tissue PO. Neuroscience letters 2020. link 40 Jennings LA, Turner M, Keebler C, Burton CH, Romero T, Wenger NS et al.. The Effect of a Comprehensive Dementia Care Management Program on End-of-Life Care. Journal of the American Geriatrics Society 2019. link 41 Graff-Radford J, Botha H, Rabinstein AA, Gunter JL, Przybelski SA, Lesnick T et al.. Cerebral microbleeds: Prevalence and relationship to amyloid burden. Neurology 2019. link 42 Kim LD, Hashmi AZ. Geriatrics update 2018: Challenges in mental health, mobility, and postdischarge care. Cleveland Clinic journal of medicine 2018. link 43 Disalvo D, Luckett T, Luscombe G, Bennett A, Davidson P, Chenoweth L et al.. Potentially Inappropriate Prescribing in Australian Nursing Home Residents with Advanced Dementia: A Substudy of the IDEAL Study. Journal of palliative medicine 2018. link 44 van Bergen JMG, Li X, Quevenco FC, Gietl AF, Treyer V, Leh SE et al.. Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiology of aging 2018. link 45 Saarelainen L, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S et al.. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. International journal of geriatric psychiatry 2018. link 46 Pollock D, Cunningham E, McGuinness B, Passmore AP. Pisa syndrome due to donepezil: pharmacokinetic interactions to blame?. Age and ageing 2017. link 47 Fenech M. Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps. Advances in nutrition (Bethesda, Md.) 2017. link 48 Flanagan KJ, Copland DA, van Hees S, Byrne GJ, Angwin AJ. Semantic Feature Training for the Treatment of Anomia in Alzheimer Disease: A Preliminary Investigation. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 2016. link 49 de Souto Barreto P, Lapeyre-Mestre M, Cestac P, Vellas B, Rolland Y. Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation. British journal of clinical pharmacology 2016. link 50 Tsoi KK, Chan JY, Leung NW, Hirai HW, Wong SY, Kwok TC. Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials. Journal of the American Medical Directors Association 2016. link 51 Inoue Y, Nakajima M, Uetani H, Hirai T, Ueda M, Kitajima M et al.. Diagnostic Significance of Cortical Superficial Siderosis for Alzheimer Disease in Patients with Cognitive Impairment. AJNR. American journal of neuroradiology 2016. link 52 Vemuri P, Knopman DS. The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochimica et biophysica acta 2016. link 53 Klohs J, Deistung A, Ielacqua GD, Seuwen A, Kindler D, Schweser F et al.. Quantitative assessment of microvasculopathy in arcAβ mice with USPIO-enhanced gradient echo MRI. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2016. link 54 Yuan M, Chen SJ, Li XL, Xu LJ. Blood Pressure and the Risk of Alzheimer's Disease: Is There a Link?. American journal of Alzheimer's disease and other dementias 2016. link 55 Sepehry AA, Lang D, Hsiung GY, Rauscher A. Prevalence of Brain Microbleeds in Alzheimer Disease: A Systematic Review and Meta-Analysis on the Influence of Neuroimaging Techniques. AJNR. American journal of neuroradiology 2016. link 56 Çerman E, Eraslan M, Çekiç O. Age-related macular degeneration and Alzheimer disease. Turkish journal of medical sciences 2015. link 57 Montastruc F, Rouanet S, Gardette V, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database. European journal of clinical pharmacology 2015. link 58 Chen YK, Xiao WM, Li WY, Liu YL, Li W, Qu JF et al.. Neuroimaging indicators of the performance of instrumental activities of daily living in Alzheimer's disease combined with cerebrovascular disease. Geriatrics & gerontology international 2015. link 59 Kovacs GG, Risser D. Clinical Neuropathology image 6-2014: Corpora amylacea replacing cornu ammonis (CACA). Clinical neuropathology 2014. link 60 Zannas AS, Okuno Y, Doraiswamy PM. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. Pharmacotherapy 2014. link 61 Liabeuf S, Gras V, Moragny J, Laroche ML, Andrejak M. Ulceration of the oral mucosa following direct contact with ferrous sulfate in elderly patients: a case report and a review of the French National Pharmacovigilance Database. Clinical interventions in aging 2014. link 62 De Lucia N, Grossi D, Trojano L. The genesis of closing-in in Alzheimer disease and vascular dementia: a comparative clinical and experimental study. Neuropsychology 2014. link 63 Fekih-Mrissa N, Klai S, Mrad M, Mansour M, Zaouali J, Gritli N et al.. Apolipoprotein E genotypes associated with Alzheimer disease and concomitant stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2014. link 64 Galindo-Garre F, Hendriks SA, Volicer L, Smalbrugge M, Hertogh CM, van der Steen JT. The Bedford Alzheimer nursing-severity scale to assess dementia severity in advanced dementia: a nonparametric item response analysis and a study of its psychometric characteristics. American journal of Alzheimer's disease and other dementias 2014. link 65 Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P et al.. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013. link 66 Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B et al.. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. European journal of clinical pharmacology 2013. link 67 Chen HF, Chang-Quan H, You C, Wang ZR, Hui W, Liu QX et al.. The circadian rhythm of arterial blood pressure in Alzheimer disease (AD) patients without hypertension. Blood pressure 2013. link 68 Costa N, Ferlicoq L, Derumeaux-Burel H, Rapp T, Garnault V, Gillette-Guyonnet S et al.. Comparison of informal care time and costs in different age-related dementias: a review. BioMed research international 2013. link 69 Stillman MJ. What’s next in Alzheimer research? Highlights from the ANA President's Symposium. Annals of neurology 2012. link 70 Messinger-Rapport BJ. Geriatrics update 2012: what parts of our practice to change, what to 'think about'. Cleveland Clinic journal of medicine 2012. link 71 Koeber R, Kluenemann HH, Waimer R, Koestlbacher A, Wittmann M, Brandl R et al.. Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012. link 72 Nourhashémi F, Gillette S, Cantet C, Stilmunkes A, Saffon N, Rougé-Bugat ME et al.. End-of-life care for persons with advanced Alzheimer disease: design and baseline data from the ALFINE study. The journal of nutrition, health & aging 2012. link 73 Mansoori N, Tripathi M, Luthra K, Alam R, Lakshmy R, Sharma S et al.. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer's and vascular dementia and their epistatic interaction. Neurobiology of aging 2012. link 74 von Känel R, Mills PJ, Mausbach BT, Dimsdale JE, Patterson TL, Ziegler MG et al.. Effect of Alzheimer caregiving on circulating levels of C-reactive protein and other biomarkers relevant to cardiovascular disease risk: a longitudinal study. Gerontology 2012. link 75 Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ et al.. Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. Journal of neurochemistry 2012. link 76 Kovacic JC, Fuster V. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. The Mount Sinai journal of medicine, New York 2012. link 77 Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N et al.. Influences of donepezil on cardiovascular system--possible therapeutic benefits for heart failure--donepezil cardiac test registry (DOCTER) study. Journal of cardiovascular pharmacology 2012. link 78 Brunnström H, Englund E. Comparison of four neuropathological scales for Alzheimer's disease. Clinical neuropathology 2011. link 79 Frisardi V, Imbimbo BP. Gerontechnology for demented patients: smart homes for smart aging. Journal of Alzheimer's disease : JAD 2011. link 80 Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Annals of neurology 2011. link 81 Samadi A, Valderas C, de los Ríos C, Bastida A, Chioua M, González-Lafuente L et al.. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorganic & medicinal chemistry 2011. link 82 Rutgers KS, van Remoortere A, van Buchem MA, Verrips CT, Greenberg SM, Bacskai BJ et al.. Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiology of aging 2011. link 83 Rogers MA, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. American journal of epidemiology 2010. link 84 Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S et al.. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. The Journal of biological chemistry 2010. link 85 Jones BW. Hospice disease types which indicate a greater need for bereavement counseling. The American journal of hospice & palliative care 2010. link 86 Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinistö L et al.. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010. link 87 Piercecchi-Marti MD, De Paula AM, Gavaudan G, Bartoli C, Pelissier-Alicot AL, Leonetti G et al.. Interpretation of neuropathological lesions: its limitations in medico-legal experts' reports. Forensic science international 2010. link 88 Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP et al.. Cancer linked to Alzheimer disease but not vascular dementia. Neurology 2010. link 89 Marks N, Berg MJ. BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis. Neurochemical research 2010. link 90 McAvinchey K, Burns A. Alzheimer disease: Perceived efficacy of antidementia drug treatment. Nature reviews. Neurology 2009. link 91 Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiology and drug safety 2009. link 92 Vatassery GT, Smith WE, Quach HT. Brains of apolipoprotein E deficient mice fed vitamin E deficient diets show alteration in handling alpha tocopherol injected into the cerebral ventricles. Journal of the neurological sciences 2009. link 93 Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A et al.. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochemistry international 2009. link 94 Giannakopoulos P, Kövari E, Herrmann FR, Hof PR, Bouras C. Interhemispheric distribution of Alzheimer disease and vascular pathology in brain aging. Stroke 2009. link 95 Obrenovich ME, Morales LA, Cobb CJ, Shenk JC, Méndez GM, Fischbach K et al.. Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. Journal of cellular and molecular medicine 2009. link 96 Dysken MW, Kirk LN, Kuskowski M. Changes in vitamin E prescribing for Alzheimer patients. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2009. link 97 van der Beek EM, Kamphuis PJ. The potential role of nutritional components in the management of Alzheimer's Disease. European journal of pharmacology 2008. link 98 Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF et al.. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008. link 99 Gallini A, Sommet A, Montastruc JL. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiology and drug safety 2008. link 100 T Cuenco K, Lunetta KL, Baldwin CT, McKee AC, Guo J, Cupples LA et al.. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Archives of neurology 2008. link